Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

August 11, 2019

“Biosimilars” are equivalent versions of monoclonal antibodies that have previously been FDA approved to treat various diseases.  Because antibodies are more complicated than simple drugs like acetaminophen and aspirin, etc., these drugs are not chemically identical to the original drug.   The main advantage of biosimilars is the reduction in